Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last?

Harmony Biosciences (HRMY) shares surged 12.7% following the announcement of robust preliminary third-quarter 2025 results, which included Wakix franchise revenues of approximately $239 million, marking a 29% year-over-year increase. The company also raised its full-year 2025 revenue guidance to a range of $845-$865 million. Despite this positive news and upward revision, the article highlights that the consensus EPS estimate for the upcoming quarter has remained unchanged, suggesting that sustained upward momentum for the stock may be challenged without further earnings estimate revisions.

Analysis

Harmony Biosciences (HRMY) shares experienced a significant 12.7% surge in the last trading session, driven by robust volume and the announcement of strong preliminary third-quarter 2025 results. The company reported approximately $239 million in revenue for its Wakix franchise, marking a substantial 29% year-over-year increase. This positive performance contrasts with the stock's 1.8% loss over the preceding four weeks.

The preliminary results prompted Harmony Biosciences to raise its full-year 2025 revenue guidance to a new range of $845-$865 million, an increase from the earlier projection of $820-$860 million. For the upcoming Q3 2025 report on November 4th, the company anticipates quarterly earnings of $0.83 per share, representing a 5.1% year-over-year growth, alongside revenues of $220.95 million, an 18.8% increase from the prior year.

However, a key consideration for sustained momentum is the unchanged consensus EPS estimate for the quarter over the past 30 days. Empirical research suggests a strong correlation between trends in earnings estimate revisions and near-term stock price movements, indicating that the absence of upward revisions could temper further appreciation despite the positive preliminary revenue figures. The stock currently holds a Zacks Rank #3 (Hold).

Key Decisions for Investors

• Investors should closely monitor Harmony Biosciences' official Q3 2025 earnings report on November 4th for confirmation of preliminary figures and any additional forward-looking statements.
• Evaluate any subsequent revisions to analyst EPS estimates, as a lack of upward movement in these estimates could limit sustained stock price appreciation despite strong revenue performance.
• Consider the implications of the current Zacks Rank #3 (Hold) and the cautious tone regarding sustained momentum, suggesting a balanced approach to position sizing and risk management.